Antimalarial drug resistance is an international problem that requires a co-ordinated, international response

Imported resistance has rendered ineffective the two affordable malaria drugs which have been the mainstay of malaria treatment in Africa for forty years, according to experts writing today in the journal Science.

Scientists from the London School of Hygiene and Tropical Medicine and colleagues from institutions in the USA, South Africa and Thailand believe that mutations causing drug resistance in Plasmodium falciparum (the parasite which causes the most deadly form of malaria) originated in South East Asia and were then imported and spread across Africa – leading to the demise of both chloroquine and sulfadoxine pyrimethamine as effective, affordable treatments.

Dr. Cally Roper of the London School of Hygiene & Tropical Medicine, the lead author of the article, comments: 'Several replacement treatments are already compromised by the emergence of resistance in Asia. We suggest that careful thought should be given to preventing further import of resistant parasites, perhaps by the screening and treatment of passengers travelling from South East Asia or South America to Africa.

'The widespread introduction of artemisinin-based combination therapy could also help to minimise the rate at which resistant parasites can spread. Most importantly, these data demonstrate that antimalarial drug resistance is an international problem that requires a co-ordinated, international response'.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Study finds potential for antidiabetic drugs to modify osteoarthritis risk